Investigational vaccine protects cattle from respiratory syncytial virus

March 10, 2017, NIH/National Institute of Allergy and Infectious Diseases
Credit: National Cancer Institute

A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, protected cattle from respiratory syncytial virus (RSV) infection, according to research published online in npj Vaccines on March 8. The research was conducted by a team of experts at NIAID, the Pirbright Institute based in the United Kingdom, and the Institute for Research in Biomedicine in Switzerland. The version of RSV that naturally infects cattle is closely related to human RSV, so the results suggest that a similar human RSV vaccine construct may provide protection in humans, according to the study authors.

RSV causes the majority of respiratory disease in cattle, resulting in significant economic costs to the industry. In humans, RSV can cause serious bronchiolitis and pneumonia in young children, the elderly, and children and adults with compromised immune systems. RSV infections are estimated to cause more than 250,000 human deaths annually around the world. There is no licensed vaccine to prevent RSV infection in humans, and vaccines currently in use for cattle have noted safety and effectiveness problems.

The investigational vaccine contains a single, structurally engineered RSV protein that elicited high levels of neutralizing antibodies in mice. The protein is a stabilized version of the RSV fusion (F) glycoprotein in its initial conformation, called pre-F. Other vaccines have used the same protein in its final conformation (called post-F), but investigators found the immune response to that vaccine was much lower.

For this study, investigators immunized five 3-6 week-old calves with the pre-F protein via two injections four weeks apart. They vaccinated another five calves with a post-F protein, while a third group of five calves received two placebo injections of saline. Four weeks after the second immunization, investigators infected all three groups with RSV. The calves vaccinated with the pre-F protein had high levels of neutralizing antibodies (more than 100-fold higher than those that received the post-F protein), and four of five were protected from RSV viral replication in the upper and lower respiratory tracts. In contrast, RSV was detected in all calves immunized with either the post-F or placebo.

Together the results support further evaluation of pre-F vaccines against RSV in both cattle and in humans, the authors write. NIAID recently began testing a similar construct in a Phase 1 human trial.

Explore further: Respiratory syncytial virus vaccine enters clinical testing

More information: Baoshan Zhang et al, Protection of calves by a prefusion-stabilized bovine RSV F vaccine, npj Vaccines (2017). DOI: 10.1038/s41541-017-0005-9

Related Stories

Respiratory syncytial virus vaccine enters clinical testing

February 22, 2017
A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The ...

Epstein-Barr virus vaccine elicits potent neutralizing antibodies in animals

August 13, 2015
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators have developed an experimental, nanoparticle-based vaccine against Epstein-Barr ...

Vaccine against respiratory syncytial virus shows promise in early trial

November 4, 2015
Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the ...

Experimental MERS vaccine shows promise in animal studies

July 28, 2015
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Two-vaccine Ebola regimen shows promise in early-stage clinical trial

April 19, 2016
An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. Results from the study are described in the April ...

Study offers clues to making vaccine for infant respiratory illness

April 25, 2013
An atomic-level snapshot of a respiratory syncytial virus (RSV) protein bound to a human antibody represents a leap toward developing a vaccine for a common—and sometimes very serious—childhood disease. The findings, ...

Recommended for you

Study: Ibuprofen, acetaminophen more effective than opioids in treating dental pain

April 17, 2018
Opioids are not among the most effective—or longest lasting—options available for relief from acute dental pain, a new examination of the results from more than 460 published studies has found.

Text messaging tool may help fight opioid epidemic

April 17, 2018
A new automated text messaging service may curb opioid abuse and reduce the likelihood of relapse while also decreasing treatment costs, according to researchers at Washington University School of Medicine and Epharmix, a ...

Marijuana-based drug gets positive review from US agency

April 17, 2018
A closely watched medicine made from the marijuana plant reduces seizures in children with severe forms of epilepsy and warrants approval in the United States, health officials said Tuesday.

Post-surgical opioids can, paradoxically, lead to chronic pain

April 16, 2018
Giving opioids to animals to quell pain after surgery prolongs pain for more than three weeks and primes specialized immune cells in the spinal cord to be more reactive to pain, according to a new study by the University ...

Animal study suggests common diabetes drug may also help with nicotine withdrawal

April 5, 2018
In a mouse study, a drug that has helped millions of people around the world manage their diabetes might also help people ready to kick their nicotine habits.

20 years after Viagra, Pfizer seeks another miracle drug

April 1, 2018
It has been 20 years since Viagra was introduced, and Pfizer is still searching for another drug with as much earning power as the revolutionary blue erection pill.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.